BioCryst Pharmaceuticals, Inc. (BCRX) Presents at Jefferies London Healthcare Conference 2025 Transcript
BioCryst Pharmaceuticals, Inc. ( BCRX ) Jefferies London Healthcare Conference 2025 November 19, 2025 12:00 PM EST Company Participants Jon Stonehouse - CEO & Executive Director Charles Gayer - President & Chief Commercial Officer Babar Ghias - CFO & Head of Corporate Development Conference Call Participants Maurice Raycroft - Jefferies LLC, Research Division Presentation Maurice Raycroft Jefferies LLC, Research Division Hi, everyone. My name is Maury Raycroft, and I'm one of the biotech analysts at Jefferies.
BioCryst Pharmaceuticals, Inc. (BCRX) Q3 2025 Earnings Call Transcript
BioCryst Pharmaceuticals, Inc. ( BCRX ) Q3 2025 Earnings Call November 3, 2025 8:30 AM EST Company Participants Nick Wilder Jon Stonehouse - CEO & Executive Director Charles Gayer - President & Chief Commercial Officer William Sheridan - Chief Development Officer Babar Ghias - CFO & Head of Corporate Development Conference Call Participants Laura Chico - Wedbush Securities Inc., Research Division Stacy Ku - TD Cowen, Research Division Steven Seedhouse - Cantor Fitzgerald & Co., Research Division Maurice Raycroft - Jefferies LLC, Research Division Brian Abrahams - RBC Capital Markets, Research Division Jonathan Wolleben - Citizens JMP Securities, LLC, Research Division John Todaro - Needham & Company, LLC, Research Division Huidong Wang - Barclays Bank PLC, Research Division Presentation Operator Good day, and welcome to BioCryst Third Quarter 2025 Earnings Conference Call. [Operator Instructions] Please note this event is being recorded.
BioCryst Pharmaceuticals (BCRX) Earnings Expected to Grow: Should You Buy?
BioCryst (BCRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BioCryst (BCRX) Soars 6.1%: Is Further Upside Left in the Stock?
BioCryst (BCRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
BioCryst Pharmaceuticals, Inc. (BCRX) M&A Call Transcript
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX ) M&A Call October 14, 2025 8:00 AM EDT Company Participants Nick Wilder Jon Stonehouse - CEO & Executive Director Charles Gayer - President & Chief Commercial Officer Babar Ghias - CFO & Head of Corporate Development Conference Call Participants Stacy Ku - TD Cowen, Research Division Laura Chico - Wedbush Securities Inc., Research Division Steven Seedhouse - Cantor Fitzgerald & Co., Research Division Brian Abrahams - RBC Capital Markets, Research Division Jonathan Wolleben - Citizens JMP Securities, LLC, Research Division Huidong Wang - Barclays Bank PLC, Research Division Maurice Raycroft - Jefferies LLC, Research Division John Todaro - Needham & Company, LLC, Research Division Jessica Fye - JPMorgan Chase & Co, Research Division Presentation Operator Good day, and welcome to the BioCryst Pharmaceuticals Conference Call. [Operator Instructions] Please note this event is being recorded.
Down 14.3% in 4 Weeks, Here's Why BioCryst (BCRX) Looks Ripe for a Turnaround
BioCryst (BCRX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
BioCryst Pharmaceuticals, Inc. (BCRX) Presents at Cantor Global Healthcare Conference 2025 Transcript
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX ) Cantor Global Healthcare Conference 2025 September 4, 2025 9:45 AM EDT Company Participants Charles Gayer - President Babar Ghias - CFO & Head of Corporate Development Conference Call Participants Steven Seedhouse - Cantor Fitzgerald & Co., Research Division Presentation Steven Seedhouse MD & Biotechnology Analyst Good morning, everyone, and thanks so much for joining us for our next session. I'm Steve Seedhouse with the Cantor Biotech team.
BioCryst Pharmaceuticals, Inc. (BCRX) Q2 2025 Earnings Call Transcript
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX ) Q2 2025 Earnings Conference Call August 4, 2025 8:30 AM ET Company Participants Babar Ghias - CFO & Head of Corporate Development Charles K. Gayer - President Donald S.
BioCryst Pharmaceuticals (BCRX) Surpasses Q2 Earnings and Revenue Estimates
BioCryst Pharmaceuticals (BCRX) came out with quarterly earnings of $0.15 per share, beating the Zacks Consensus Estimate of $0.03 per share. This compares to a loss of $0.06 per share a year ago.
BioCryst Pharmaceuticals Before Q2 Earnings: How to Play the Stock
BCRX gears up for Q2 results with Orladeyo growth in focus, but 2025 EPS forecasts dip as investors eye pipeline progress.
BioCryst Pharmaceuticals (BCRX) Reports Next Week: Wall Street Expects Earnings Growth
BioCryst (BCRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BioCryst (BCRX) Upgraded to Strong Buy: What Does It Mean for the Stock?
BioCryst (BCRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
